Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye (PEMDAC)
A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma
Sponsor: Merck Sharp & Dohme LLC
This PHASE2 trial investigates Metastatic Uveal Melanoma and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Sep 2023 — Jan 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- Syndax Pharmaceuticals
- Vastra Gotaland Region
For direct contact, visit the study record on ClinicalTrials.gov .